26 results about "MMP9" patented technology

The invention relates to the technical field of gene therapy and drug development, and provides application of a UCH37 inhibitor in preparation of a drug for treating osteoporosis. The expression level of UCH37 in blood of osteoporosis patients is obviously higher than that of UCH37 in blood of healthy people, and the UCH37 is in positive correlation with osteoclast active markers such as NFATC1 and MMP9. The UCH37 inhibitor is applied to preparation of the medicine for treating osteoporosis and directly targets UCH37, the curative effect does not depend on the expression change of ADRM1, no matter the ADRM1 of osteoporosis patients is in a low or high expression state, an osteoclast activation pathway can be stably blocked, the consistency of treatment effects of different individuals is ensured, the range of applicable people of the medicine is expanded, and the application prospect is broad. The compound has the characteristics of clear action mechanism and wide application range, and provides important theoretical basis and conversion prospect for developing novel and efficient medicines for treating osteoporosis.

The invention discloses a plant lactobacillus AR195 strain and application thereof in preparation of a medicine for preventing and / or treating lung cancer, and belongs to the technical field of microorganisms. Through verification, the plant lactobacillus AR195 can inhibit the growth of lung cancer cells, also has certain prevention and treatment effects in a lung cancer mouse model, and can reduce the tumor burden of a BALB / c mouse lung cancer model by reducing MMP9 secretion, so that the plant lactobacillus AR195 can be used for preventing and assisting in treating lung cancer. Meanwhile, the accumulation of the AR195 bacteria in the lung can be improved to the maximum extent through atomization administration, and meanwhile, the adverse side effects of the whole body are reduced. A new drug source is provided for treatment of lung cancer, a novel treatment strategy is provided for treatment of lung cancer by probiotics, and treatment of lung cancer and development of a novel treatment method are facilitated. Meanwhile, the application range of the plant lactobacillus AR195 strain is widened, and a novel treatment strategy is provided for a potential mechanism of treating lung cancer by probiotics.

Provided herein are compositions and methods for modulating MMP9 expression. In some instances, compositions and methods are used to treat a neurodegenerative disorder. In some instances, the compositions comprise antisense oligonucleotides.

The application discloses application of CCL3-AS1 in regulating stability of carotid artery plaque, overexpression of CCL3-AS1 induces inflammatory activity of macrophages and secretion of MMP9, promotes plaque rupture and thrombosis; on the contrary, knockdown of CCL3-AS1 inhibits inflammatory activity of macrophages and secretion of MMP9, reduces plaque rupture and thrombosis; in addition, the application also discloses that CCL3-AS1 enhances MMP9 mRNA stability by combining with hnRNP-K, thereby increasing MMP9 expression and secretion and degrading fibrous cap collagen. The application discloses important role of CCL3-AS1 in stability of carotid artery plaque and a molecular mechanism, provides a new diagnostic marker and a treatment target, not only provides a new direction for research on atherosclerosis related diseases, but also provides a new tool and a means for clinical diagnosis and treatment.

The application discloses application of a GPR146 inhibitor in preparation of a drug for treating wet age-related macular degeneration. The application finds that GPR146 is significantly up-regulated in expression in a mouse model of laser-induced CNV and a mouse model of subretinal fibrosis. In mice, shRNA is used to knock down GPR146, thereby significantly inhibiting CNV, subretinal fibrosis and inflammation. In an in-vitro experiment, siRNA targeting GPR146 can inhibit the in-vitro neovascular function of endothelial cells, such as proliferation, migration and tube formation, and reduce immune cell adhesion and transendothelial cell migration. In addition, targeting GPR146 can also inhibit the expression of TGF-beta, Fibronectin (FN), alpha-SMA, Col1A, MMP9 and other fibrosis-promoting molecules by endothelial cells. Meanwhile, targeting GPR146 can also inhibit the proliferation and migration of smooth muscle cells and reduce the expression of the above fibrosis-promoting molecules. The above results all show that targeting GPR146 can significantly inhibit CNV formation, inflammation and subretinal fibrosis, and has good therapeutic effect.

The application relates to the field of natural medicines, and discloses an alkaloid, a preparation method and application thereof, the alkaloid having a structure shown in formula I and pharmaceutically acceptable salts thereof. The alkaloid is separated from a n-butanol extraction part of an ethanol extract of Dendrobium huoshanense stems through silica gel column chromatography and a preparation thin layer separation technology, and the structure is identified through nuclear magnetic resonance and high-resolution mass spectrometry. Through cell experiments, it is verified that the alkaloid prepared in the application can significantly relieve inflammation induced by LPS, inhibit human gastric cancer cell (AGS) proliferation and promote apoptosis; molecular docking analysis shows that the alkaloid prepared in the application can be significantly docked with active sites of induced iNOS, IL-6, TNF-alpha and MMP9, and the binding energy is-9.5~(-8.6) kcal / mol.

The present application relates to a tumor prognosis evaluation gene set and its application, the evaluation gene set is composed of 5 genes, the 5 genes are as follows: MKI67 , PCNA , VEGF-A , MMP9 , TRIM11 , the tumor is selected from any one of colorectal cancer, lung cancer, pancreatic cancer.Compared with the prior art, the present application constructs a multi-type tumor prognosis prediction model MKI67 , PCNA , VEGF-A , MMP9 , TRIM11 Synergistic effect is carried out from four core pathways of tumor proliferation, angiogenesis, invasion and metastasis, abnormal regulation, the detection accuracy of single index is significantly improved, and it is suitable for colorectal cancer, lung cancer and pancreatic cancer.

The application discloses application of a petroleum ether extract of a root of a roadside green plant in preparation of a drug for treating colorectal cancer by regulating a PI3K / AKT / MDM2 / p53 pathway. In the application, the petroleum ether extract of the root of the roadside green plant for treating colorectal cancer is obtained by petroleum ether reflux extraction of the root of the roadside green plant. Pharmacological experiments show that the petroleum ether extract of the root of the roadside green plant treats colorectal cancer by regulating the PI3K / AKT / MDM2 / p53 signal pathway through down-regulating p-PI3K / PI3K and p-AKT / AKT ratio, up-regulating p-MDM2 and down-regulating p53 level; the extract has an anti-malignant proliferation effect, induces G1 phase arrest by targeting CDK2, up-regulating p21, down-regulating Cyclin E1-CDK2 and Cyclin D1-CDK4; the extract induces HCT-116 cell apoptosis through a mitochondrial pathway by up-regulating Bax / Bcl-2, reducing ΔΨm, releasing Cyt C, activating Caspase-9 / 3 and cleaving PARP; the extract inhibits migration and invasion of HCT-116 cells by targeting MMP9, down-regulating MMP-2, MMP-9 and N-cadherin expression and up-regulating E-cadherin expression. In addition, the extract inhibits growth of a transplanted tumor in a nude mouse transplanted tumor model by inducing apoptosis of transplanted tumor cells.

The invention relates to the technical field of biological medicine and tissue engineering, in particular to a tissue engineering blood vessel and a preparation method and application thereof. The tissue engineering blood vessel is obtained by modifying interleukin 24 (IL-24) on the surface of an acellular blood vessel, after the tissue engineering blood vessel is transplanted into a body, the number of CD31 + and CD34 + cells can be remarkably increased, and infiltration of M2 type macrophages (CD163 +) on the surface of the blood vessel is remarkably increased; the expression of HIF-1 alpha (hypoxia marker) and MMP9 is obviously reduced; the expression of the nerve specific protein S-100 is obviously increased, thrombosis and intimal hyperplasia are effectively inhibited, and the patency rate of transplanted blood vessels is obviously increased.

The invention relates to a fusion polypeptide for diabetes wound repair and a pharmaceutical composition thereof, and discloses a sequence design and a preparation method of the fusion polypeptide FP-DW01-Chol, and a temperature-sensitive hydrogel composition containing the polypeptide and MitoQ. The fusion polypeptide contains a TREM2 agonist domain, an AGE-RAGE blocking domain, an MMP9 recognition cleavage site, an Angiopoietin-2 mimic peptide fragment and a cholesterol modification terminal, and can activate anti-inflammatory polarization of macrophages, block a chronic inflammation pathway and respond to a wound enzyme environment to release an angiogenesis promoting fragment. The pharmaceutical composition takes poloxamer 407 / 188 as a temperature-sensitive carrier, realizes cooperative delivery of polypeptide and MitoQ, and has the advantages of slow release, skin retention and stability. In-vitro and db / db mouse model experiments prove that the composition can remarkably promote high-glucose damaged cell activity recovery, inhibit inflammatory factor release, accelerate wound closure, promote angiogenesis and tissue remodeling, provides a multi-mechanism synergistic and local long-acting treatment scheme for diabetic refractory wounds, and has important clinical transformation value.

This invention belongs to the field of protein technology and relates to a peptide that prevents collagen loss and its preparation method. The amino acid sequence of the peptide is KSYELPDGQVITIG, with the key active fragment being ELPDGQVIT. The peptide is obtained by enzymatic hydrolysis of defatted grain insect powder using alkaline protease, trypsin, papain, neutral protease, and flavor protease. This peptide can inhibit the expression of MMP1 and MMP9 in L929 cells after UVA irradiation, thus alleviating collagen loss.

The invention relates to application of an Arteridin gene as a biomarker in preparation of a product for auxiliary diagnosis of abdominal aortic aneurysm, clinical specimens and animal experiments find that the expression of Arteridin in occurrence of abdominal aortic aneurysm is remarkably increased, which indicates that Arteridin can be used as the biomarker for auxiliary diagnosis of abdominal aortic aneurysm; the invention also relates to a product for down-regulating the expression of Arterin and an application of the product in preparation of drugs for treating abdominal aortic aneurysm, the product comprises siRNA and shRNA of a targeted Arterin gene and AAV for coding the sequence of the shRNA, and after specific knockdown of Arterin by smooth muscle cells is realized, in an Elatase-induced abdominal aortic mouse model, the expression of Arterin is reduced, and the expression of Arterin is reduced. The diameter of the aneurysm is reduced, the occurrence rate is reduced, the elastin destruction degree is reduced, the expression quantity of vascular remodeling genes MMP2 and MMP9 is reduced, and the difference is obvious compared with that of a control group; the result shows that Arteridin is expected to become a target spot for treating abdominal aortic aneurysm.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of two biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least one of Matrix metalloproteinase-9 (MMP9), S100 calcium-binding protein A8 (S100A8), and Hemoglobin subunit beta (Hb-beta); or of the proteins Matrix metalloproteinase-9 (MMP9) and at least one of S 100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

The present invention relates to a macrophage genetically engineered to overexpress interleukin-10 (IL-10) or IL-10 in combination with matrix metallopeptidase 9 (MMP9). Such macrophages are useful for treating cirrhosis in a subject. In particular, the subject can be treated after having experienced a first liver decompensation event requiring hospitalization of the subject. The subject can have experienced a subsequent decompensation event prior to treatment.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

A method for diagnosing a urinary tract infection in a subject, the method comprising measuring the expression level of one or more of proteins selected from MMP9, IL8, MPO and HNE in a urine sample obtained from the subject; and comparing the expression level of the one or more proteins to a reference level; wherein when the protein expression levels are increased or there is a positive expression level when compared to the reference level, the subject is predicted to have a urinary tract infection.

The application discloses application of isoprenyl cysteine carboxymethyltransferase as a rheumatoid arthritis treatment target in preparation of a rheumatoid arthritis treatment drug. The application finds that the expression of ICMT is down-regulated after NSUN2 is knocked out, further research on the expression level of ICMT in RA FLS finds that the mRNA and protein expression of RA FLS ICMT is obviously up-regulated, the cell migration and invasion ability is reduced after ICMT is knocked down, and the expression of MMPs such as MMP1, MMP3 and MMP9 of RA FLS is obviously inhibited. The above results show that ICMT can regulate the abnormal migration and invasion of RA FLS, and targeting ICMT can become a new means to prevent RA joint destruction. Therefore, the application provides an effective treatment target for RA, and provides a new idea for clinical treatment of RA.

The invention discloses application of calycosin-7-glucoside in preparation of a medicine for inhibiting Treg cell infiltration in liver cancer, relates to the field of biological medicine, and discloses application of calycosin-7-glucoside in preparation of a medicine for inhibiting regulatory T cell (Treg) infiltration in hepatocellular carcinoma. The calycosin-7-glucoside realizes the application by inhibiting the activity and / or expression of matrix metalloproteinase 9 (MMP9); according to the application of calycosin-7-glucoside in preparation of the medicine for inhibiting Treg cell infiltration in liver cancer, the new functions of targeting tumor immune microenvironment and specifically inhibiting Treg cell infiltration of the traditional Chinese medicine active ingredient CG are found and confirmed for the first time, the medicinal value of CG is expanded, and a brand new direction is provided for clinical transformation of CG.

Disclosed herein are antibodies binding to MMP9 protein, and use thereof for detecting or diagnosing endometrial cancer, preferably in a gynecological fluid, preferably uterine or cervical fluids.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a low stromal gene signature score. In some aspects, the low stromal gene signature score is determined by measuring the expression of a panel of stromal genes in a tumor sample obtained from the subject, wherein the stromal gene panel comprises at least four genes selected from CDH1, CDH2, MMP1, MMP2, ITGA1, ITGA2, ITGA3, ITGA5, ITGA7, ITGA11, TGFB1, and TGFB1; at least four genes selected from TGFB1, TGFBR2, ACTA2, COL4A1, TAGLN, SH3PXD2A, TWIST1, ZEB1, and ZEB2; or MMP2 and MMP9.

The application discloses application of vidarabine phosphate in preparation of a medicine for treating liver ischemia-reperfusion injury, and relates to the field of biological medicines. The application finds that vidarabine phosphate can obviously reduce serum liver enzyme levels, obviously reduce GZMB accumulation in liver tissues and expression of inflammation-related factors including Il-1beta, Tnf-alpha and Mmp9, indicates that liver inflammation reaction is reduced, and reduces liver cell apoptosis-related protein cleaved-caspase 3 levels and liver histological injury. In summary, the application first finds application of vidarabine phosphate in treating liver ischemia-reperfusion injury, which can play a role in improving liver enzyme levels and reducing liver inflammatory injury, and has wide clinical application value.

This invention discloses an oligopeptide, its preparation method, and its applications. The optimal oligopeptide, with the amino acid sequence LYVPHWN, was obtained through LC-MS / MS analysis, computer-aided screening, and network pharmacology. This oligopeptide exhibits high affinity for key targets such as MMP9, TNF, BCL2, and STAT3, and demonstrates good biocompatibility and low toxicity. At concentrations ≤1600 μg / mL, it shows no significant toxicity to Caco-2 cells. Furthermore, it significantly increases GSH content, decreases MDA content, and enhances SOD activity in Caco-2 cells in an oxidative stress model, effectively regulating the intracellular antioxidant system and alleviating oxidative stress.

The invention discloses a preparation method of a nucleic acid co-delivery system and application of the nucleic acid co-delivery system in scar treatment, and belongs to the technical field of biological medicine and gene therapy, the preparation method comprises the following steps: S1, reagent preparation: respectively preparing anhydrous ethanol solutions of ionizable cationic liposome SM-102, cholesterol, distearic acid phosphatidylcholine and DMG-PEG2000 with the concentration of 10 mg / mL; s2, lipid phase mixing: mixing the four solutions in the step S1 according to a molar ratio of 50: 38.5: 10: 1.5; s3, preparing a water phase solution, wherein RNA is composed of ID3 mRNA and MMP9 siRNA according to the mass ratio of 5: 1; s4, mixing and purifying, carrying out vortex oscillation for 30 seconds, and controlling the mass ratio of the liposome to the RNA to be 20: 1; s5, resuspending: resuspending with PBS and diluting the LNP precipitate obtained in the step S4, so that the final concentration of the encapsulated RNA is 50 mu g / mL; and S6, storage: storing the prepared and synthesized lipid nanoparticle solution at 4 DEG C. The dual-nucleic acid synergistic anti-scar curative effect is remarkable, the nucleic acid delivery efficiency is high, the biocompatibility is good, the safety is high, one medicine has multiple purposes, and the application range is wide.

The invention relates to the technical field of biological medicine, in particular to a biomarker combination, a kit of the biomarker combination and application of the biomarker combination in diagnosis of acute Stanford B-type aortic dissection (ATBAD). The biomarker combination comprises serum amyloid protein A1 (SAA1), serum amyloid protein A2 (SAA2), C-reactive protein (CRP), neutrophil elastinase (ELANE), matrix metalloenzyme 9 (MMP9), nest protein 1 (NID1), mannose binding lectin 2 (LMAN2) and proprotein convertase subtilisin / kexin type 9 (PCSK9), and the biomarker combination can realize high-sensitivity and high-accuracy detection of ATBAD. And the anti-interference capability is excellent.

The present invention relates to a macrophage, genetically engineered to overexpress Interleukin-10 (IL-10) or IL-10 in combination with Matrix Metallopeptidase 9 (MMP9). Such a macrophage may be for use in treatment of an inflammatory condition in a subject such as inflammatory organ damage. The inflammatory condition may be acute or chronic and may involve a fibrotic element.

Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL / MMP9 complex. Serum NGAL (ng / ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p<0.0001). Serum NGAL (ng / ml) was significantly lower in the acute / recurrent cohort (n=78, 71.3±32.1) than in the control and, than in the chronic cohort (n=90, 88.3±55, p=0.03). Similarly, Serum NGAL / MMP9 (ng / ml) levels was lower in the whole CSCR cohort (44.5±39.6) as compared to the controls (77.6±47.8, p<0.0001). Serum NGAL / MMP9 (ng / ml) were significantly lower in the acute / recurrent cohort (37.6±37.9) than in the control and, than in the chronic cohort (50.5±40.3, p=0.002). Thus, in both forms of CSCR serum NGAL and NGAL / MMP9 are lower than in the control population, providing a biological link between the two forms and a potential susceptibility to oxidative stress and innate immune dysregulation. Systemic LCN2 being elevated in other retinal diseases, it represents a specific biomarker for CSCR.